1. Refractory

    Comments Leave a Comment

    1-15 of 99 1 2 3 4 5 6 7 »
    1. Mentioned In 99 Articles

    2. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.

      ...hase. We report the feasibility of busulfan/melphalan (BuMel) after I-MIBG therapy with HSCR in patients with refractory or relapsed metastatic neuroblastoma. From November 2008 to March 2015, 9 patients received BuMel a...
      Read Full Article
    3. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

      .... Vorinostat pharmacokinetic testing and histone acetylation assays were performed. Twenty-nine patients with refractory or relapsed neuroblastoma were enrolled and 28 were evaluable for dose escalation decisions. Median...
      Read Full Article
      Mentions: Refractory NANT
    4. PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma

      PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma
      ...etherlands Cancer Institute, Amsterdam, the Netherlands. The majority of high-risk neuroblastoma patients are refractory to, or relapse on, current treatment regimens, resulting in 5-year survival rates of less than 50%....
      Read Full Article
    5. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

      ...in, we describe the rationale and design of the first study of venetoclax in pediatric patients with relapsed/refractory malignancies: a Phase I trial investigating the safety and pharmacokinetics of venetoclax monothera...
      Read Full Article
      Mentions: Refractory
    6. Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma

      I have read and accept the Wiley Online Library Terms and Conditions of Use. I have read and accept the Wiley Online Library Terms and Conditions of Use. Use the link below to share a full-text version of this article with your friends and colleagues. Learn more.
      Read Full Article
      Mentions: Refractory ALK
    7. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

      .... Vorinostat pharmacokinetic testing and histone acetylation assays were performed. Twenty‚Äźnine patients with refractory or relapsed neuroblastoma were enrolled and 28 were evaluable for dose escalation decisions. Median...
      Read Full Article
      Mentions: Refractory NANT
    8. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      ... the urgent need to identify novel therapeutic targets. The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. ...
      Read Full Article
    9. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.

      ... worse PFS and OS. NANTRCv1.0 response of at least SD is associated with better OS in patients with recurrent/refractory neuroblastoma. Patient and tumor characteristics may predict response and outcome. Identifying thes...
      Read Full Article
      Mentions: Refractory NANT MYCN
    10. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma

      ... worse PFS and OS. NANTRCv1.0 response of at least SD is associated with better OS in patients with recurrent/refractory neuroblastoma. Patient and tumor characteristics may predict response and outcome. Identifying thes...
      Read Full Article
      Mentions: Refractory NANT MYCN
    11. Anti-GD2 Car T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma

      Anti-GD2 Car T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma
      ...and a Phase II or expansion phase. Paediatric or young adult patients with relapsed High Risk and/or relapsed/refractory Neuroblastoma will be enrolled in the study. Eligible patients will undergo leukapheresis in order ...
      Read Full Article
      Mentions: Refractory
    12. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma.

      ....18K322A, cytokines and NK cells is feasible and resulted in clinically meaningful responses in patients with refractory/recurrent neuroblastoma. Further studies of this approach are warranted in patients with relapsed a...
      Read Full Article
    13. Anticancer efficacy of p-dodecylaminophenol against high-risk and refractory neuroblastoma cells in vitro and in vivo.

      ...oma is an aggressive and drug-resistant refractory cancer. Neuroblastoma is an aggressive and drug-resistant refractory cancer. The human high-risk neuroblastoma cell line, SK-N-AS (non-amplified N-myc) is derived from ...
      Read Full Article
      Mentions: Refractory
    14. 1-15 of 99 1 2 3 4 5 6 7 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about Refractory

    1. We demonstrate for the first time that low-dose IL-2 is safe in children with advanced, steroid refractory chronic GVHD and results in a high clinical response rate.
      In Low-dose treatment with Il2 across studies shows benefits in chronic graft-versus host
    2. We demonstrate for the first time that low-dose IL-2 is safe in children with advanced, steroid refractory chronic GVHD and results in a high clinical response rate.
      In Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease